Der Nervenarzt
-
Gastrointestinal dysfunction is frequent during all stages of Parkinson's disease. The entire gastrointestinal tract becomes involved and symptoms include sialorrhea, dysphagia (difficulties swallowing), delayed gastric emptying, absorption problems and constipation. These non-motor symptoms can be manifested even prior to the initial Parkinson diagnosis, i.e. during the so-called premotor phase of the disorder and may serve as prodromal markers of the early non-motor disease phase. ⋯ The therapeutic options for impaired upper gastrointestinal tract motility are still limited. Sialorrhea can be reduced by prescribing anticholinergics or injections of botulinum toxin and the peristalsis can be modulated by domperidone. In the lower gastrointestinal tract, constipation can be conservatively treated by using macrogol (polyethylene glycol) and, in the future, perhaps by serotonine (5-HT4) agonists.
-
Randomized Controlled Trial
[EuroHYP-1 trial: EU-funded therapy study on the effectiveness of mild therapeutic hypothermia for acute ischemic stroke].
Therapeutic hypothermia (TH) improves the neurological outcome in experimental brain trauma models as well as in patients suffering from cardiac arrest and perinatal asphyxia. So far the efficacy of TH has not been proven in acute ischemic stroke due to lack of clinical data. The EuroHYP-1 study will investigate whether TH with an individual target range temperature between 34 and 35 °C administered for 24 h will improve the neurological outcome in ischemic stroke patients treated within 6 h from symptom onset. The target patient number of 1,500 to be included in EuroHYP-1 is sufficiently powered to detect the efficacy of TH.